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Abstract
OBJECTIVES—To evaluate the day-night variation of acute myocardial infarction (MI) in patients
with obstructive sleep apnea (OSA).
BACKGROUND—OSA has a high prevalence and is characterized by acute nocturnal
hemodynamic and neurohormonal abnormalities that may increase the risk of MI during the night.
METHODS AND RESULTS—We prospectively studied 92 patients with MI, for which the time
of onset of chest pain was clearly identified. The presence of OSA was determined by overnight
polysomnography. For patients with and without OSA we compared the frequency of MI during
different intervals of the day based on the onset time of chest pain. The groups had similar prevalence
of comorbidities. MI occurred between midnight and 6am in 32% of OSA patients and 7% of non-
OSA patients (P=0.01). The odds of having OSA in those patients whose MI occurred between
midnight and 6am was six-fold higher than in the remaining 18 hours of the day (95% C.I: 1.3 −27.3,
P=0.01). Of all patients having an MI between midnight and 6am, 91% had OSA.
CONCLUSIONS—The diurnal variation in the onset of MI in OSA patients is strikingly different
from the diurnal variation in non-OSA patients. Patients with nocturnal onset of MI have a high
likelihood of having OSA. These findings suggest that OSA may be a trigger for MI. Patients having
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nocturnal onset of MI should be evaluated for OSA, and future research should address the effects
of OSA therapy for prevention of nocturnal cardiac events.
CONDENSEND ABSTRACT—We studied 92 patients with MI, for whom the time of onset of
chest pain was clearly identified. MI occurred between midnight and 6am in 32% of OSA patients
and 7% of non-OSA patients (P=0.01). The odds of having OSA in those patients whose MI occurred
between midnight and 6am was 6 fold higher than in the remaining 18 hours of the day (95% C.I:
1.3 −27.3, P=0.01). The diurnal variation in the onset of MI in patients with OSA is strikingly
different; patients with nocturnal onset of MI have a high likelihood of having OSA.
Keywords
obstructive sleep apnea; myocardial infarction; circadian variation
INTRODUCTION
Obstructive sleep apnea (OSA) is an increasingly prevalent condition that remains
underdiagnosed and undertreated (1). OSA may increase the risk of cardiovascular diseases,
including hypertension, ischemic heart disease, stroke, heart failure, pulmonary hypertension
and cardiac arrhythmias(2,3). The prevalence of OSA is two to three-fold higher in patients
with a history of MI(4).
In the general population MI and SCD occur with a diurnal periodicity that peaks between 6am
and noon(5). In a previous study, we found that SCD was more frequent during the night in
OSA patients(6). Mechanisms of SCD could have included MI, stroke, arrhythmias, pulmonary
embolus, aortic dissection, or other cardiovascular causes.
Acute nocturnal pathophysiological responses to OSA, including hypoxemia, sympathetic
activation and surges in blood pressure, may lead to plaque rupture, coronary thrombosis, and
MI. Should OSA be a trigger of MI, we would expect a peak of onset of symptoms of MI during
the night. Whether OSA patients are more likely to have nocturnal MI has not been previously
studied.
METHODS
The study was approved by the Institutional Review Board of the Mayo Clinic, and all subjects
provided informed consent. We prospectively studied 92 patients admitted with incident MI
to our hospital. While consecutive patients were eligible, recruitment was based on exclusion
criteria listed below, on availability of research personnel, and on patients consenting to
participate. The exclusion criteria were: patients without typical chest pain; uncertain time of
onset of MI; and previous CPAP treatment.
The diagnosis of MI was made by the patients’ attending physician and confirmed by the
following: increase in creatine-phosphokinase concentration ≥2 times the upper limit of
normal, and elevation of troponin T activity (>0.03 ng/ml).
The time of onset of MI was determined by each patient’s report of the chest pain that prompted
hospital admission. This strategy to assess the time of MI has been previously validated(7).
Every subject underwent comprehensive polysomnography at 17 ± 2.4 days after MI,
performed with an attended complete overnight polysomnographic monitoring system.
Obstructive apneas and hypopneas were classified according to standard criteria(8). An apnea-
hypopnea index (AHI) ≥ 5 established the diagnosis of OSA. All polysomnographic
measurements and diagnoses were made blinded to the timing of symptoms of MI.
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Statistical analysis
Patients’ characteristics are presented as means (± SD) or percentages. Quantitative variables
were compared with a two-tailed t-test. Qualitative data and the frequency distributions of MI
for the four 6-hour intervals of the day between subjects with and without OSA were compared
with the χ2 test or Fisher’s exact test (when expected frequencies below 5 occurred). Intra-
group comparisons were conducted to determine the odds ratio of having OSA in patients who
had an MI during each 6-hour interval compared to the remaining 18 hours of the day.
RESULTS
We studied 92 patients (71 men), mean age 61 ± 13 years and BMI 30 ± 5 kg/m2. Using a
threshold of AHI ≥ 5 events/hour, OSA was present in 70% of patients. Using a more
conservative threshold of AHI ≥ 10 events/hour, about half (52%) of our patient population
was diagnosed with OSA. Patients’ characteristics are shown in Table 1. The two groups had
similar prevalence of comorbidities. There was no difference between groups regarding
medication use (Table 2 and Table 3).
The diurnal variation in the onset of MI in OSA patients was different from that observed in
non-OSA patients (Figure 1). From midnight to 6 am, the frequency of MI was significantly
higher in OSA patients compared to non-OSA patients (32% vs. 7%; p=0.01). Using a threshold
of AHI ≥ 10 events/hour we observed similar results (33% vs. 14%; p=0.03). From 6am to
noon, the frequency of MI was higher in non-OSA patients compared to OSA patients (47%
vs. 17%; p=0.003). Similar results were evident for the analyses based on three 8-hour time
intervals (Figure 2). We found no difference in the use of beta-blocker therapy and the
frequency of MI during the various intervals of the day.
Patients whose MI occurred between midnight to 6am had an odds ratio of 6 for having OSA
(95% C.I: 1.3 − 27.3, p=0.01). Of 22 patients who had an MI between midnight and 6am, 20
(91%) had OSA. If we used a more conservative threshold for OSA the likelihood of nocturnal
MI occurring in OSA patients remains significantly higher (73%).
DISCUSSION
The novel finding of this study is that OSA patients have an increased risk of MI between
midnight and 6 am, compared to non-OSA patients. Our data suggest that OSA may be a trigger
for MI, with a striking reversal in the expected diurnal timing of MI onset. Conversely, non-
OSA patients had a nadir of MI onset at night and a peak in the morning, similar to the diurnal
distribution of MI seen in the general population. Previous studies suggest that beta-blockers
(7) and diabetes(9) may attenuate the morning peak of MI. Our findings identify OSA as the
first disease condition recognized to actually reverse the usual day-night variation in the
incidence of MI.
OSA has been implicated in increased risk of MI, stroke and SCD(10,11). While OSA patients
have a higher frequency of nocturnal ST-segment depression than those without OSA(12,13),
it remained unknown whether OSA may directly cause nocturnal MI. Our findings suggest that
the pathophysiology of OSA leads to an increased risk of MI during the night.
Several acute pathophysiological mechanisms during sleep in OSA patients may be responsible
for their altered diurnal variation of MI. Cessation of airflow results in hypoxemia and
hypercapnia, with consequent activation of the chemoreflex(14) and increased sympathetic
nerve activity and blood pressure (BP) (15). Obstructed breathing with negative intra-thoracic
pressures increases cardiac wall stress(16).
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Peripheral vasoconstriction and increased cardiac output (due to changes in cardiac transmural
pressures upon termination of apneas) lead to dramatic surges in arterial BP. These
hemodynamic stresses in the setting of simultaneous hypoxemia and increased myocardial
oxygen demand may promote acute nocturnal cardiac ischemia(13,17). OSA is also associated
with factors that may increase the risk of nocturnal coronary thrombosis, including platelet
activation during sleep(18), elevated fibrinogen levels(19), increased whole blood viscosity,
and decreased fibrinolytic activity(20). These processes may be responsible for the shift in the
timing of MI from the morning hours to the night in OSA patients.
Strengths of the current study include first, its prospective design. Second is the use of complete
polysomnography, interpreted while blinded as to time of onset of MI. Third, the influence of
OSA on timing of MI onset could not be explained by comorbidities or medications, which
were similar in both groups. Potential limitations include first, the inherent uncertainty in
identifying the exact timing of onset of an MI. The pathophysiology of coronary plaque rupture
and arterial thrombosis is dynamic and occurs over varying time periods before symptoms or
signs may manifest. These limitation parallel those of the entire body of evidence that has
demonstrated the timing of MI in the general population and other subgroups(9). Previous
studies have shown a strong correlation between the timing of MI, based on cardiac biomarker
levels, and the onset of pain(7). Second, based on criteria noted earlier, we did not study every
patient admitted with MI. Therefore, our data cannot be used to estimate the overall prevalence
of OSA in patients with recent MI. Identifying the prevalence of OSA in the post-MI patient
population was not a goal of this study. Nevertheless, the characteristics of our study sample
are similar to those of the general MI patient population in Olmsted County(21) and although
the prevalence of OSA in our population is relatively high, our findings are comparable to those
noted in a prior study of OSA prevalence in the post-MI patient population(22). A third concern
relates to whether OSA developed as an acute consequence of MI. Of patients found to have
OSA on polysomnography, 76% had a high risk for OSA as assessed by the Berlin
Questionnaire, suggesting that the OSA was indeed present prior to the MI. Furthermore,
polysomnography was conducted when patients were stable. Most important, this limitation
cannot account for our findings of a higher nocturnal occurrence of MI in OSA patients. Last,
these studies represent survivors of MI, and do not necessarily represent all patients with acute
MI.
In summary, we have demonstrated that patients with OSA have an altered diurnal variation
of MI, which is consistent with the unique nocturnal pathophysiology of OSA. These findings
highlight a potential causative role of OSA in the development of acute coronary syndromes,
and suggest that nocturnal MI may contribute to the increased likelihood of nocturnal SCD
observed in OSA patients(6). Our data further suggest that those patients who experience the
onset of MI during the usual sleep hours should be evaluated for the presence of OSA. Further
research is necessary to understand the effects of OSA therapy on modifying the timing of MI
in these patients and in altering their overall risk of acute coronary syndromes and SCD.
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Figure 1.
Day–night pattern of MI based on four six-hour time intervals in OSA (64) and no-OSA (28)
patients.
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Figure 2.
Day–night pattern of MI based on three eight-hour time intervals in OSA (64) and no-OSA
(28) patients.
Sert Kuniyoshi et al. Page 8
J Am Coll Cardiol. Author manuscript; available in PMC 2009 July 29.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Sert Kuniyoshi et al. Page 9
Table 1
Characteristics of the study population at the time of myocardial infarction, according to the presence or absence of
obstructive sleep apnea.
Characteristics OSA Status
OSA (N=64) No OSA (N=28) p-value
Age, year 64 ± 12 57 ± 12 0.02
Male sex (%) 78 75 0.7
Body mass index, kg/m2 31 ± 6 28 ± 4 0.01
AHI, events/hour 22 ± 2.1 1.6 ± 0.3 <0.0001
LVEF (%) 51 ± 2 55 ± 2 0.11
Peak CK, U/L 1392 ± 296 1417 ± 264 0.9
Peak CK-MB, ng/mL 143 ± 23 134 ± 20 0.8
Hypertension (%) 57 57 1
Hypercholesterolemia (%) 67 61 0.6
Diabetes mellitus (%) 25 11 0.1
Prior MI (%) 13 18 0.5
Congestive heart failure (%) 5 0 0.5
Current smoker (%) 27 39 0.2
Systolic BP, mmHg* 120 ± 2 116 ± 3 0.2
Diastolic BP, mmHg* 69 ± 1 67 ± 2 0.4
Cholesterol, mg/dL 178 ± 5 161 ± 6 0.06
Triglycerides, mg/dL 153 ± 14 101 ± 11 0.02
HDL cholesterol, mg/dL 43 ± 2 41 ± 2 0.4
LDL cholesterol, mg/dL 108 ± 4.9 101 ± 6.2 0.4
Fasting Glucose, mg/dL 118 ± 4 112 ± 5 0.4
AHI= Apnea hypopnea index, BP = Blood pressure (*values at the time of PSG), CK = creatine kinase, CK-MB = creatine kinase MB isoenzyme, HDL
= High-density lipoproteins, LDL = low-density lipoproteins, LVEF= left ventricular ejection fraction, measured within one week after MI, MI =
myocardial infarction, OSA = obstructive sleep apnea.
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Table 2
Medications taken at the time of myocardial infarction, according to the presence or absence of obstructive sleep apnea.
OSA Status
OSA (N=64) No OSA (N=28) p-value
Aspirin (%) 35 25 0.4
Beta-blockers (%) 25 29 0.7
ACE inhibitors (%) 16 21 0.5
Statins (%) 35 39 0.7
Calcium antagonists (%) 9 7 1
ACE = angiotensin converting enzyme, OSA = obstructive sleep apnea.
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Table 3
Medications at the time of the sleep study, according to the presence or absence of obstructive sleep apnea
OSA Status
OSA (N=64) No OSA (N=28) p-value
Aspirin (%) 98 89 0.08
Beta-blockers (%) 100 96 0.3
ACE inhibitors (%) 73 78 0.6
Statins (%) 98 93 0.2
Calcium antagonists (%) 3 0 1
ACE = angiotensin converting enzyme, OSA = obstructive sleep apnea.
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